• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Big job cuts coming

Quote












Rinvoq is massive underperforming nationally as well as Skyrizi underperforming in Gi. Cash flow getting tighter and this company will need more restructuring as the volume of reps are not justified.
 




You all do realize they already cut the entire HS salesforce for Humira?

Rheum just expanded salesforce at the turn of the year.

Gastro is launching new indications in key brands.


Tell me more about these massive layoffs in immunology? Seems like you all have no idea what you’re talking about.
 




The division that needs to be worried is Eye Care. Nothing in the pipeline, LOEs coming hard for the glaucoma drops, vuity shitting the bed, xen and Durysta underperforming...
 












anonymous said:
Eye Care can’t get any thinner than it did in 2022 other than going away completely.
Click to expand...

They'll let the entire drops force go as soon as there's a generic Lumigan. Maybe they'll keep Durysta and Xen because at least they have something to offer for future value.

Sad for the drops folks; but at the end of the day everything's going off patent (except Vuity, which has been the largest Rx flop in the past 10-15 years... literally a joke at this point) and there's not anything out there worth buying. The cash cow, Restasis, is gone as well; the only other reason you need drop reps in the field is throwing Refresh into samples closets and you could get a contract force for 1/4 the cost.
 




anonymous said:
Neuro is about to get more indications. What are you talking about clown?
Click to expand...
Classic abbvie, get a new indication, flood the field with reps target reach the right message with the right people the right number of times...blah blah,,,,then after the saturation is over and providers are crying uncle, the hacksaw comes out
 








anonymous said:
Classic abbvie, get a new indication, flood the field with reps target reach the right message with the right people the right number of times...blah blah,,,,then after the saturation is over and providers are crying uncle, the hacksaw comes out
Click to expand...


Neuro is in for an abrupt shift soon. Once the drug isn’t FREE anymore (that’s soon) then it will be a lot tougher. Hoops to get through and patient switches since the cost is a lot more for our drug than theirs. Looking for another job? You better . Offices will be getting pissed. The jig is up
 








anonymous said:
Neuro is in for an abrupt shift soon. Once the drug isn’t FREE anymore (that’s soon) then it will be a lot tougher. Hoops to get through and patient switches since the cost is a lot more for our drug than theirs. Looking for another job? You better . Offices will be getting pissed. The jig is up
Click to expand...

Hasn't been free for over a year and the other one hasnt been free for 4 months.. offices werent pissed if u walk them through it. Spoken like a true troll or rep that doesnt know how to do their job... or a competitor trying to stir the pot
 




Can’t answer pharmacy or offices about the path moving forward with coverage in neuro. Customers starting to get nervous about our product moving forward. Insurance will choose the others that cost less first. It’s going to get tougher. I am a good rep but I’m looking. By summer this wont be so fun .
 




anonymous said:
Can’t answer pharmacy or offices about the path moving forward with coverage in neuro. Customers starting to get nervous about our product moving forward. Insurance will choose the others that cost less first. It’s going to get tougher. I am a good rep but I’m looking. By summer this wont be so fun .
Click to expand...

Niiiiiiikooooooooooo

LOL
 








anonymous said:
Can’t answer pharmacy or offices about the path moving forward with coverage in neuro. Customers starting to get nervous about our product moving forward. Insurance will choose the others that cost less first. It’s going to get tougher. I am a good rep but I’m looking. By summer this wont be so fun .
Click to expand...
 












Top Bottom
Back
Quote